BRAF and neoplasm: For patients with tumors that are difficult to resect or require extensive surgery (stage IVb) and who have the BRAF V600E mutation, neoadjuvant dabrafenib plus trametinib can improve the chances of achieving a complete tumor resection with a reduced extent of surgery and lower surgical morbidity [33].